Ready to play
Ready to play
A recent study has shown that the drug tirzepatide outperforms other obesity medications in the GLP-1 hormone agonist class in terms of effectiveness, as it helped individuals without diabetes lose more than 20% of their weight. Semaglutide and liraglutide ranked second and third, with weight losses of 15% and 8%, respectively. Liraglutide required daily injections, whereas the newer medications are administered with weekly doses. The results also confirmed that weight loss may not always be permanent after stopping treatment, as patients can regain part of their weight within a year.
Notice: This Is an AI-Generated Summary
Comments (0)